Analyzing Absci (ABSI) and Its Competitors
Absci (NASDAQ:ABSI – Get Rating) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its rivals? We will compare Absci to similar companies based on the strength of its profitability, risk, earnings, valuation, dividends, analyst recommendations and institutional ownership.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Absci and its rivals, as provided by MarketBeat.com.
| sell ratings | hold ratings | Buy rating | Strong Buy Ratings | rating score | |
| absci | 1 | 3 | 3 | 0 | 2.29 |
| Absci Competitors | 104 | 761 | 1299 | 30 | 2.57 |
Absci currently has a consensus target price of $24.00, suggesting a potential upside of 579.89%. As a group, “Commercial physical research” companies have a potential upside of 46.20%. Given Absci’s higher possible upside, equities analysts clearly believe Absci is more favorable than its rivals.
Institutional & insider ownership
40.0% of Absci shares are held by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are held by institutional investors. 11.4% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
profitability
This table compares Absci and its rivals’ net margins, return on equity and return on assets.
| net margins | return on equity | return on assets | |
| absci | -2,633.14% | -36.19% | -22.99% |
| Absci Competitors | -260.35% | -8.25% | -2.96% |
Valuation & Earnings
This table compares Absci and its rivals revenue, earnings per share (EPS) and valuation.
| Gross revenue | Net Income | Price/earnings ratio | |
| absci | $4.78 million | -$100.96 million | -1.06 |
| Absci Competitors | $2.80 billion | $101.15 million | 11.95 |
Absci’s rivals have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Absci rivals beat Absci on 11 of the 12 factors compared.
Absci Company Profile (Get Rating)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for Absci Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Absci and related companies with MarketBeat.com’s FREE daily email newsletter.